Journal of General Internal Medicine

, Volume 17, Issue 9, pp 717–720 | Cite as

Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly

  • David Blackburn
  • Janet Hux
  • Muhammad MamdaniEmail author
Brief Report


We conducted a population-based cohort study using administrative databases to quantify the association between oral and inhaled corticosteroid use and onset of diabetes mellitus in the elderly. Proton pump inhibitor (PPI) users were used as a control group. Relative to PPI users (N=53,845), oral corticosteroid users (N=31,864) were more likely to develop diabetes (adjusted rate ratio [aRR], 2.31; 95% confidence interval [95% CI], 2.11 to 2.54); however, inhaled corticosteroid users (N=38,441) were not (aRR, 1.03; 95% CI, 0.93 to 1.14). The estimated number needed to harm for continuous use of oral corticosteroids relative to PPIs over 1, 2, and 3 years of use were 41, 23, and 16, respectively.

Key words

corticosteroids diabetes drug-induced diabetes elderly 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Delaunay F, Khan A, Cintra A, et al. Pancreatic β cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest. 1997;100:2094–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Conn H, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol. 1972;49:329–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Smyllie H, Connolly C. Incidence of serious complications of corticosteroid therapy in respiratory disease. Thorax. 1968;23:571–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Jindal R, Sidner R, Milgrom M. Post-transplant diabetes mellitus: the role of immunosuppression. Drug Saf. 1997;16:242–57.PubMedGoogle Scholar
  6. 6.
    Gurwitz J, Bohn R, Glynn R, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101.PubMedCrossRefGoogle Scholar
  7. 7.
    Faul JL, Tormey W, Tormey V, Burke C. High dose inhaled corticosteroids and dose dependent loss of diabetic control. BMJ. 1998;317:1491.PubMedGoogle Scholar
  8. 8.
    Faul JL, Cormican LJ, Tormey VJ, et al. Deteriorating diabetic control associated with high-dose inhaled budesonide. Eur Respir J. 1999;14:242–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Hux J, Bica A, Flintoft V, Ivis F. Population based estimates of the incidence and the prevalence of diabetes in Ontario. Diabetes. 2000;49(Suppl 1):388.Google Scholar
  10. 10.
    Blanchard JF, Ludwig S, Wajda A, et al. Incidence and prevalence of diabetes in Manitoba, 1986–1991. Diabetes Care. 1996;19:807–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Robson J. Information needed to decide about cardiovascular treatment in primary care. BMJ. 1997;314:277–80.PubMedGoogle Scholar
  12. 12.
    Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients’ acceptance of treatment. Med Decis Making. 1995;15:152–7.PubMedCrossRefGoogle Scholar
  13. 13.
    McAlister FA, O’Connor AM, Wells G, Grover SA, Laupacis A. When should hypertension be treated? The different perspectives of Canadian family physicians and patients. CMAJ. 2000;163:403–8.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 2002

Authors and Affiliations

  • David Blackburn
    • 1
  • Janet Hux
    • 2
    • 4
    • 3
  • Muhammad Mamdani
    • 1
    • 4
    Email author
  1. 1.Received from the University of Toronto Faculties of PharmacyTorontoCanada
  2. 2.MedicineTorontoCanada
  3. 3.Sunnybrook and Women’s College Health Sciences CentreTorontoCanada
  4. 4.Institute for Clinical Evaluative SciencesTorontoCanada

Personalised recommendations